DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria

Information source: Karolinska Institutet
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Premenstrual Dysphoric Disorder; Premenstrual Syndrome

Intervention: paroxetine (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Karolinska Institutet

Official(s) and/or principal investigator(s):
Mikael SG Landen, MD, PhD, Principal Investigator, Affiliation: Karolinska Institutet, Stockholm, Sweden

Summary

The objective of this study is to explore the onset of action when serotonin reuptake inhibitors are used to treat premenstrual dysphoric disorder

Clinical Details

Official title: A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine When Used for the Treatment of Premenstrual Dysphoria

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: The number of patients reaching sustained remission (irritability) for each time point

Secondary outcome: Self rated irritability at each time point

Detailed description: Whereas serotonin reuptake inhibitors (SRIs) usually require weeks of treatment to effectively counteract depressed mood or anxiety, several studies suggest that they may reduce the symptoms irritability and anger more rapidly. In line with this, SRIs have been shown to reduce certain symptoms, including irritability, in women with premenstrual dysphoric disorder (PMDD) when the drug only is administered from ovulation to menstruation only, which indicates an onset of action of 10 days or less. How fast this effect appears in terms of hours or days is, however, not known. The objective of this study was to explore this issue.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.

Criteria:

Inclusion Criteria:

- The patient should have participated in an ongoing placebo-controlled trial regarding

the effect of paroxetine in PMD; to be included in that trial, she must have fulfilled the diagnostic criteria A-C of PMDD in DSM-IV and certain other inclusion and exclusion criteria which are listed in appendix 1.

- The patient should a) have been given paroxetine during the previous trial, b) have

reported that she has been "much improved" or "very much improved" by this treatment, c) have displayed a marked reduction in VAS-rated irritability during treatment, and d) have reported that she has found the side-effects tolerable.

- The patient should display at least a 50% increase in VAS-rated irritability during

the luteal phase (mean of last five days prior to menses) as compared the follicular phase (days 6-10) during one cycle of pretreatment symptom rating (without medication).

- The patient should have given written informed consent to participate in the study.

Exclusion Criteria:

- Any concomitant psychiatric disorder for which SRIs are known to be effective.

- Any other concomitant psychiatric disorder that, in the investigator's opinion, would

render the patient unsuitable for the study.

- Any somatic disorder that, in the investigator's opinion, would render the patient

unsuitable for the study.

- Any ongoing medication which, in the opinion of the investigator, would render the

patient unsuitable for the study. Examples of medications that preclude participation in the study are: 1) any psychotropic drug, with the exception of the occasional use of hypnotics, 2) any hormonal preparation, with the exception of thyroid hormone, 3) anti-coagulants, and 4) 5HT1D agonists. Occasional use of analgesic compounds does not preclude participation.

- Patient characteristics which, in the opinion of the investigator, are likely to

reduce compliance with the protocol.

Locations and Contacts

The Psychiatric clinic, Sahlgrenska University Hospital, Göteborg SE43180, Sweden
Additional Information

Starting date: October 2000
Last updated: December 6, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017